Evidence map›Paper›PMID 40741322›Full record

ArticleAdvances in radiation oncology2025

Spine Stereotactic Body Radiation Therapy for a Patient With a Metallic Implant in Low-Field Magnetic Resonance-Guided Linear Accelerator: A Case Report.

Hiroki Nakayama, Hiroyuki Okamoto, Kae Okuma, Ayaka Nagao, Yuki Tsunoda, Satoshi Nakamura, Takahito Chiba, Tetsu Nakaichi, Miki Yonemura, Riki Oshika and 12 more

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Hiroki NakayamaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Hiroyuki OkamotoRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Kae OkumaDepartment of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Ayaka NagaoDepartment of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Yuki TsunodaDepartment of Radiological Technology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Satoshi NakamuraRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Takahito ChibaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Tetsu NakaichiRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Miki YonemuraDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Riki OshikaDepartment of Radiation Oncology, Hamamatsu Medical Center, Shizuoka, Japan.
Yuta KobayashiDepartment of Radiation Safety and Quality Assurance Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Hironori KishidaDepartment of Radiation Safety and Quality Assurance Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Shoki NakamuraRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Masato NishitaniRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Shuka NishinaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Takumi SakamotoEURO MEDITECH CO., LTD. Proposal & Relation Sales, Japan.
Hana EndoRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Junichi KuwaharaDepartment of Radiological Technology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Yasunori ShutoDepartment of Radiological Technology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Masataka UedaRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Tomoya KanedaNational Hospital Organization Tokyo Medical Center, Department of Radiation Oncology, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise in radiation therapy challenges facing the management of pain and neurologic symptoms from vertebral metastasis has paralleled advances in cancer treatment and patient prognosis. Surgical options include decompression to alleviate spinal cord compression symptoms, with consideration for spinal stability through fixation using titanium alloy implants. Previous studies comparing radiation alone with postoperative irradiation following decompression surgery showed superior functional outcomes. Stereotactic body radiation therapy (SBRT), which concentrates radiation on the tumor while sparing surrounding organs, has clinical advantages when combined with surgery. However, the accurate delineation of targets and organs, particularly the spinal cord of a patient with metallic implants, is difficult with computed tomography and magnetic resonance (MR) images because of metal artifacts and registration errors. The low-field MR-guided radiation therapy (the low-field MRgRT) system offers advantages in target delineation with metal artifact suppression because of its associated low-magnetic field and no need for registration between a computed tomography image and an MR image for the delineation of targets and organs because the low-field MRgRT system uses the MR image acquired by itself as the primary image. The advantages make the low-field MRgRT suitable for spine SBRT, especially for patients with metallic implants. Here, we present a case of successful postoperative spine SBRT using the low-field MRgRT, ensuring the identification of the spinal cord, and safe and accurate treatment in a patient with metallic implants. The conclusion highlights the low-field MRgRT as a viable option for postoperative spine SBRT, which is particularly beneficial for patients with metallic implants, ensuring treatment safety and accuracy.

Identifiers

PMID40741322
PMCPMC12304675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.